Sign up to save your podcasts
Or
Share Focus on Cedric Francois, MD, PhD, CEO, Apellis Pharmaceuticals
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Focus on Cedric Francois, MD, PhD, CEO, Apellis Pharmaceuticals
Dr. Francois discusses the epidemiology of geographic atrophy, the pathophysiology of complement inhibition in the treatment of GA, and the latest information on Apellis' Phase 2 and Phase 3 clinical trials.
View all episodes
By Retina Synthesis
4.5
88 ratings
Dr. Francois discusses the epidemiology of geographic atrophy, the pathophysiology of complement inhibition in the treatment of GA, and the latest information on Apellis' Phase 2 and Phase 3 clinical trials.
More shows like Retina Synthesis
View all
New Retina Radio by Eyetube
18 Listeners
White Coat Investor Podcast
2,446 Listeners
The Daily
112,734 Listeners
WSJ Minute Briefing
673 Listeners
Up First from NPR
56,473 Listeners
Bogleheads On Investing Podcast
594 Listeners
MedEdTalks - Ophthalmology
4 Listeners
American Journal of Ophthalmology Podcasts Collection
11 Listeners
Experts InSight
52 Listeners
RETINA Journal Podcasts
10 Listeners
Ophthalmology Journal
18 Listeners
Talking Euretina
1 Listeners
RetinaRounds™
0 Listeners
The Last Invention
837 Listeners